It is very uncertain whether mechanical thrombectomy changes major adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether mechanical thrombectomy changes minor adverse events compared with pulse spray technique (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether mechanical thrombectomy changes minor adverse events compared with continuous infusion (very low certainty).
It is very uncertain whether surgical thrombectomy changes major adverse events compared with continuous infusion (very low certainty).
It is very uncertain whether surgical thrombectomy changes minor adverse events compared with continuous infusion (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether continuous Infusion changes minor adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether pharmacomechanical thrombolysis (Cragg® catheter) changes minor adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether pharmacomechanical thrombolysis (Cragg® catheter) changes major adverse events compared with pulse spray technique (very low certainty).
It is very uncertain whether surgical thrombectomy changes major adverse events compared with pulse spray technique (very low certainty).
The review found no eligible studies for this question.
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
Lesinurad 400 mg plus febuxostat CONTINUED showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CONTINUED (low certainty).
Lesinurad 400 mg plus febuxostat CROSS showed no clear difference in total adverse events compared with lesinurad 200 mg plus febuxostat CROSS (low certainty).
Pegloticase every two weeks (biweekly) showed no clear difference in total adverse events compared with placebo (moderate certainty).
It is very uncertain whether cyclosporin changes adverse events: ESKD compared with placebo or no treatment (very low certainty).
Mycophenolate sodium + oral steroids showed no clear difference in adverse events: death compared with oral steroids alone (low certainty).
Berotralstat showed no clear difference in adverse events(during compared with placebo or active control (moderate certainty).